Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

Bonadonna G(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-717

Valagussa P(1995)Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 901-6

Moliterni A(1998)Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group Lancet 352 930-42

Zambetti M(2001)Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial J Clin Oncol Off J Am Soc Clin Oncol 19 602-11

Brambilla C(2003)Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol Off J Am Soc Clin Oncol 21 976-83

Henderson IC(2006)Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial J Clin Oncol Off J Am Soc Clin Oncol 24 5664-71

Berry DA(2008)Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol Off J Am Soc Clin Oncol 26 44-53

Demetri GD(1998)Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study J Clin Oncol Off J Am Soc Clin Oncol 16 3486-92

Cirrincione CT(2001)Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23 J Clin Oncol Off J Am Soc Clin Oncol 19 931-42

Goldstein LJ(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 432-44

Bonadonna G(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-717

Valagussa P(1995)Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 901-6

Moliterni A(1998)Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group Lancet 352 930-42

Zambetti M(2001)Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial J Clin Oncol Off J Am Soc Clin Oncol 19 602-11

Brambilla C(2003)Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol Off J Am Soc Clin Oncol 21 976-83

Henderson IC(2006)Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial J Clin Oncol Off J Am Soc Clin Oncol 24 5664-71

Berry DA(2008)Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol Off J Am Soc Clin Oncol 26 44-53

Demetri GD(1998)Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study J Clin Oncol Off J Am Soc Clin Oncol 16 3486-92

Cirrincione CT(2001)Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23 J Clin Oncol Off J Am Soc Clin Oncol 19 931-42

Goldstein LJ(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 432-44